Table 2.
Standardized mortality ratios among 2-year survivors of autologous HCT
|
Entire cohort
|
Standard risk of relapse
|
High risk of relapse
|
||||
|---|---|---|---|---|---|---|
| No. of deaths (%) | SMR (95% CI) | No. of deaths (%) | SMR (95% CI) | No. of deaths (%) | SMR (95% CI) | |
| All patients | 251 | 13.0 (11.5-14.7) | 117 | 10.2 (8.4-12.1) | 133 | 17.1 (14.3-20.1) |
| Sex | ||||||
| Male | 154 (61.4) | 10.4 (8.8-12.1) | 75 | 8.6 (6.8-10.7) | 78 | 12.7 (10.1-15.7) |
| Female | 97 (38.6) | 17.3 (14.0-20.9) | 42 | 12.2 (8.8-16.2) | 55 | 25.2 (18.9-32.3) |
| Age at HCT, y | ||||||
| Less than 18 | 31 (12.4) | 60.2 (40.9-83.3) | 21 | 57.4 (35.5-84.5) | 10 | 68.5 (32.6-117.6) |
| 18 to 45 | 133 (53.4) | 19.0 (15.9-22.4) | 42 | 10.7 (7.7-14.2) | 90 | 29.3 (23.6-35.7) |
| More than 45 | 87 (34.3) | 7.4 (5.9-9.0) | 54 | 7.5 (5.7-9.7) | 33 | 7.2 (4.9-9.9) |
| Year of HCT | ||||||
| 1980 to 1984 | 7 (2.8) | 49.2 (19.5-92.3) | 3 | 71.6 (13.5-175.5) | 4 | 39.8 (10.4-88.4) |
| 1985 to 1989 | 71 (28.3) | 22.8 (17.8-28.5) | 31 | 22.6 (15.3-31.2) | 39 | 22.5 (16.0-30.1) |
| 1990 to 1994 | 112 (44.2) | 12.5 (10.3-14.9) | 54 | 10.1 (7.6-12.9) | 58 | 16.1 (12.2-20.5) |
| 1995 to 1999 | 61 (24.7) | 8.7 (6.6-10.9) | 29 | 6.2 (4.1-8.6) | 32 | 13.6 (9.3-18.8) |
| Primary diagnosis | ||||||
| AML | 24 (9.6) | 6.4 (4.1-9.3) | 23 | 6.5 (4.1-9.5) | 1 | 4.6 (0.0-18.0) |
| ALL | 24 (9.6) | 43.8 (28.0-63.1) | 20 | 43.8 (26.7-65.2) | 4 | 43.5 (11.3-96.7) |
| NHL | 113 (44.6) | 9.6 (7.9-11.5) | 51 | 7.8 (5.8-10.1) | 62 | 11.8 (9.1-15.0) |
| HD | 90 (36.3) | 28.2 (22.6-34.3) | 23 | 24.0 (15.2-34.8) | 67 | 29.6 (22.9-37.1) |
HCT indicates hematopoietic cell transplantation; SMR, standardized mortality ratio; 95% CI, 95% confidence interval; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease.